Watch Finding Coronavirus Vaccine Could Take More Than a Year: Novartis CEO Vas Narasimhan Says - Bloomberg
Novartis's Vas Narasimhan on AI, Data Science for Company Operations
Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and more - STAT
Novartis on X: "Join us in giving a warm welcome to @VasNarasimhan, who from today is the new CEO of Novartis. Congrats Vas! #NovartisNews https://t.co/sM3oE8sCWg" / X
Novartis CEO Vas Narasimhan visits Slovenia - Lek
Vas Narasimhan talks to Monocle - Novartis Live. Magazine
The CEO of Novartis on Developing Drugs During a Pandemic | WIRED
Novartis - Today we announced appointment of Vasant (Vas) Narasimhan, M.D., Global Head of Drug Development and Chief Medical Officer, as the new CEO of Novartis, effective February 1, 2018. We thank
Novartis Has Dropped Some Cancer Drugs From Pipeline, CEO Says | Barron's
Novartis CEO Vas Narasimhan on Culture, Strategy and Change
CEO's letter - Novartis Novartis in Society Integrated Report 2022
Vas Narasimhan | One Young World
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Unternehmenskultur bei Novartis | Novartis Deutschland
Novartis CEO Vas Narasimhan: How to be a boss in an “unbossed” company - YouTube
Vasant Narasimhan | Novartis
Novartis' CEO on gene therapy, innovation, and the company pivot - STAT
How Novartis's CEO Learned From His Mistakes and Got Help From an Unlikely Quarter - WSJ
Novartis CEO: Expect continued growth in 2023 - YouTube
Novartis chief criticises EU move to control pharma licensing in emergencies | Financial Times
Novartis boss warns US drug pricing reform poses risk to public health | Financial Times
Novartis renews its commitment to neglected tropical diseases and malaria elimination
Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft | Reuters
Novartis chief's 2018 take-home pay suffers—not from Cohen but from low-grade returns | Fierce Pharma
